Cargando…

Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making

Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional I...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandel, Philipp, Wenzel, Mike, Hoeh, Benedikt, Welte, Maria N., Preisser, Felix, Inam, Tahir, Wittler, Clarissa, Humke, Clara, Köllermann, Jens, Wild, Peter, Würnschimmel, Christoph, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Karakiewicz, Pierre I., Chun, Felix K.-H., Becker, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293248/
https://www.ncbi.nlm.nih.gov/pubmed/34207594
http://dx.doi.org/10.3390/curroncol28030197
_version_ 1783724994346352640
author Mandel, Philipp
Wenzel, Mike
Hoeh, Benedikt
Welte, Maria N.
Preisser, Felix
Inam, Tahir
Wittler, Clarissa
Humke, Clara
Köllermann, Jens
Wild, Peter
Würnschimmel, Christoph
Tilki, Derya
Graefen, Markus
Kluth, Luis A.
Karakiewicz, Pierre I.
Chun, Felix K.-H.
Becker, Andreas
author_facet Mandel, Philipp
Wenzel, Mike
Hoeh, Benedikt
Welte, Maria N.
Preisser, Felix
Inam, Tahir
Wittler, Clarissa
Humke, Clara
Köllermann, Jens
Wild, Peter
Würnschimmel, Christoph
Tilki, Derya
Graefen, Markus
Kluth, Luis A.
Karakiewicz, Pierre I.
Chun, Felix K.-H.
Becker, Andreas
author_sort Mandel, Philipp
collection PubMed
description Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.
format Online
Article
Text
id pubmed-8293248
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82932482021-07-22 Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making Mandel, Philipp Wenzel, Mike Hoeh, Benedikt Welte, Maria N. Preisser, Felix Inam, Tahir Wittler, Clarissa Humke, Clara Köllermann, Jens Wild, Peter Würnschimmel, Christoph Tilki, Derya Graefen, Markus Kluth, Luis A. Karakiewicz, Pierre I. Chun, Felix K.-H. Becker, Andreas Curr Oncol Article Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7–10. Conclusions: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa. MDPI 2021-06-09 /pmc/articles/PMC8293248/ /pubmed/34207594 http://dx.doi.org/10.3390/curroncol28030197 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mandel, Philipp
Wenzel, Mike
Hoeh, Benedikt
Welte, Maria N.
Preisser, Felix
Inam, Tahir
Wittler, Clarissa
Humke, Clara
Köllermann, Jens
Wild, Peter
Würnschimmel, Christoph
Tilki, Derya
Graefen, Markus
Kluth, Luis A.
Karakiewicz, Pierre I.
Chun, Felix K.-H.
Becker, Andreas
Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
title Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
title_full Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
title_fullStr Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
title_full_unstemmed Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
title_short Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
title_sort immunohistochemistry for prostate biopsy—impact on histological prostate cancer diagnoses and clinical decision making
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293248/
https://www.ncbi.nlm.nih.gov/pubmed/34207594
http://dx.doi.org/10.3390/curroncol28030197
work_keys_str_mv AT mandelphilipp immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT wenzelmike immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT hoehbenedikt immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT weltemarian immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT preisserfelix immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT inamtahir immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT wittlerclarissa immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT humkeclara immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT kollermannjens immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT wildpeter immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT wurnschimmelchristoph immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT tilkiderya immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT graefenmarkus immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT kluthluisa immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT karakiewiczpierrei immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT chunfelixkh immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking
AT beckerandreas immunohistochemistryforprostatebiopsyimpactonhistologicalprostatecancerdiagnosesandclinicaldecisionmaking